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Abstract: Retinoblastoma, the most common childhood eye cancer, presents in two forms: heritable or
sporadic. Heritable retinoblastoma is caused by a germline mutation in the RB1 gene. Early diagnosis
of children at risk of inheriting an RB1 mutation is crucial to achieve optimal clinical outcome. Currently,
the majority of genetic testing is performed on newborns, which has multiple disadvantages for both
families and the healthcare system. We have developed a non-invasive prenatal diagnosis (NIPD)
service for retinoblastoma, available from 8 weeks’ gestation, which uses a combination of massively
parallel sequencing (MPS) techniques, dependent on the inheritance model. Detection of paternal or
suspected de novo RB1 variants is achieved through amplicon-based MPS. NIPD of a fetus at risk of
maternal inheritance is performed using capture-based targeted sequencing and relative haplotype
dosage analysis. In addition, we show proof of principle of how capture-based sequencing can be
used for de novo variants unsuitable for amplicon-based testing. In total, we report the NIPD of
15 pregnancies, results of which show 100% concordance with all postnatal testing performed at the
time of publication (n = 12) with remaining pregnancies ongoing. NIPD of retinoblastoma therefore
offers a viable alternative to newborn genetic testing.
Keywords: retinoblastoma; prenatal diagnosis; non-invasive; cell-free DNA
1. Introduction
Retinoblastoma (Rb) is the most common childhood eye cancer with an incidence of
~1:15,000–1:20,000 live births (reviewed in [1]). Over 99% of retinoblastomas are due to bi-allelic
inactivation in the RB1 gene, caused by either two somatic mutations or an initial germline mutation
followed by a subsequent somatic hit as described in Knudson’s two-hit hypothesis [2]. Approximately
40% of Rb cases carry a germline mutation and can be further classified as either familial, where the
patient has inherited a predisposition to Rb from an affected parent, or sporadic heritable, where there
is no family history and Rb has resulted from a de novo pre-zygotic germline mutation [3]. A child
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is at 50% risk of inheriting an RB1 mutation if either of their parents carry a germline RB1 variant.
Furthermore, siblings of a patient with a de novo RB1 mutation have an approximate 1% risk of also
carrying the mutation due to germ cell mosaicism [4]. Where a family history is known, early diagnosis
is paramount to achieve optimal clinical outcome with the least treatment morbidity. Currently, the
majority of testing is performed on postnatal cord blood, with the aim of achieving a diagnostic result
within 14 days of birth. This tight timeline can pose challenges to both the healthcare system and
parents. It requires considerable co-ordination of the antenatal, paediatric, genetic laboratory and
retinoblastoma services. Even within a nationalised health service, this is not easy to achieve and is
further challenged in couples not wishing hospital deliveries. The laboratory costs are also increased
by having to run the analysis as an urgent test. For parents undergoing predictive genetic testing,
this is an additional psychological burden at a time when bonding with a new baby is important and
individuals may feel especially vulnerable. Furthermore, many families may live several hours away
from their retinoblastoma service providers and have to arrange, and travel to, a precautionary early
appointment in case the results are delayed.
A current alternative to newborn screening is prenatal testing, either by chorionic villi sampling
(CVS) at 11 weeks’ gestation or amniocentesis at 16 weeks. However, a recent Dutch review reports
only 12% of parents with an Rb family history take up this service [5] and our experience suggests
this number is even lower in the UK. This is likely partly due to the invasive nature of the test, which
includes a surgical procedure with an often-reported 0.5% chance of miscarriage [6].
Non-invasive prenatal diagnosis (NIPD), which analyses cell-free fetal DNA within the mother’s
blood, offers all the potential advantages of a prenatal result while avoiding the issues associated with
an invasive procedure. Unlike non-invasive prenatal testing (NIPT) screening, NIPD is considered
a definitive diagnostic test, where confirmation by invasive means is not required [7]. Furthermore,
NIPD testing is available from 8 weeks’ gestation, earlier than both CVS and amniocentesis. If a
positive genetic result is obtained, an Rb management plan could be put in place prior to birth. Parents
would be able to come to terms with the diagnosis in a timely manner before the arrival of their child.
A negative result would give peace of mind to the parents and could mean a child avoids unnecessary
neonatal ophthalmic checks.
While there have been several reports in the literature showing case studies and proof of principles
for NIPD assays for single gene disorders (reviewed in [8]), there has been relatively little clinical
implementation. The majority of NIPD services that have been developed are designed to detect
paternal or de novo variants [9,10] as the detection of maternally inherited alleles is more challenging
due to the presence of cell-free DNA (cfDNA) of maternal origin in maternal plasma. We previously
developed NIPD for X-linked [11] and autosomal recessive disorders [12] which allows both maternal
and paternal inheritance to be determined by relative haplotype dosage (RHDO) analysis. This method
overcomes the difficulty in detecting maternal variants and, as it uses linkage-based approach, does
not require test development for family-specific variants, some of which may be unsuitable for direct
detection. These tests are now part of our routine clinical service in the UK, providing non-invasive
prenatal diagnosis for pregnancies at risk of cystic fibrosis (CF), spinal muscular atrophy (SMA),
Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), with over 150 pregnancies
tested since September 2016 [7].
Here, we outline the development and implementation of clinical NIPD testing for retinoblastoma.
We describe a comprehensive, cost-effective NIPD service available to families with a positive family
history of the disease, which uses a combined assay approach. Paternally inherited and likely de
novo mutations are detected directly using amplicon-based massively parallel sequencing (MPS),
whereas NIPD of maternally inherited mutations uses a capture-based targeted MPS approach and
haplotype analysis. In addition, we also show how capture-based targeted MPS can be adapted for the
direct detection of larger paternal or likely de novo mutations, which would not be possible using an
amplicon-based test.
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2. Material and Methods
2.1. Patient Samples
Initial recruitment and validation samples were collected as part of the NIPSIGEN study
(“NIPSIGEN: clinical translation of NIPD for SGDs”; REC approval number: 13/NW/0580). The delivery
of NIPD by RHDO or direct amplicon-based mutation analysis is now part of routine clinical service
delivered for the UK population by the West Midlands Regional Genetic service. Subsequent families
described in this series provided consent for prenatal genetic testing in line with standard clinical
practice. Plasma from non-pregnant healthy donors was also collected as part of the NIPSIGEN study.
To be eligible for testing, families needed to have a known family history of retinoblastoma, with a
confirmed molecular diagnosis and appropriate reference samples (maternal and paternal or maternal,
paternal and previous child) available. Samples were accepted for analysis from pregnant patients
with singleton pregnancies at >8 weeks of gestation, confirmed by a scan.
2.2. Sample Processing and DNA Extraction
Maternal and control plasma was isolated from 10 mL blood samples received in Streck (La Vista,
USA) BCT tubes and stored at −80 ◦C. Cell-free DNA was extracted either from 4 mL of plasma using
the QIAsymphony Circulating Nucleic Acid kit (Qiagen, Hilden, Germany) into a final volume of 60 µL
AVE buffer or from 2 mL plasma using a QIAamp DSP MiniElute virus kit (Qiagen, Hilden, Germany)
into a final volume of 50 µL AVE buffer. Genomic DNA (gDNA) was extracted from leukocytes by
QIAsymphony DSP DNA kit (Qiagen, Hilden, Germany).
2.3. Amplicon-Based MPS
Custom primers for each mutation were designed using Primer Quest Tool (IDT, Coralville,
USA). Illumina sequence tags were then added. Primer validation was performed using a maternal
gDNA sample plus gDNA from the affected family member (paternal or previous affected child) and
control cfDNA. NIPD testing for a variant was offered following successful validation where the
following conditions had been met: (1) mutant allele detected in the affected family member at the
expected frequency, and (2) absence of the mutant allele in maternal gDNA and control cfDNA. In total,
nine primer sets were designed and validated (Supplementary Table S1), eight of which were then
subsequently used for NIPD testing.
NIPD testing comprised of sequencing maternal cfDNA in duplicate plus maternal gDNA,
paternal gDNA and gDNA from a previous affected child where applicable. Five cfDNA samples from
non-pregnant healthy individuals were also included as controls. Fetal fraction was determined by
amplifying an additional maternal cfDNA sample using a primer pool targeting 42 informative single
nucleotide polymorphisms (SNPs) across the genome (Supplementary Table S2).
Polymerase chain reactions (PCRs) were carried out using 20 µL (~3–9 ng) cfDNA or 10 ng gDNA
plus 10 µL of Multiplex PCR mastermix (Qiagen, Hilden, Germany) and 200 nM of each primer in
a final reaction volume of 20 µL. For PCRs using the fetal fraction primer pool, 10 µL of Multiplex
PCR Plus mastermix (Qiagen, Hilden, Germany) was used. Cycling conditions were 95 ◦C for 5 min,
followed by 30 cycles of 95 ◦C for 30 s, 60 ◦C for 3 min and 72 ◦C for 30 s, followed by 68 ◦C for
30 min. Amplicons were purified using Zymo-Spin Columns (Zymo Research, Irvine, USA) according
to the manufacture’s instructions. Purified PCR products were then amplified for a second time to
incorporate individual 6 bp barcodes for each sample. Indexing PCRs were carried out using 2 µL
of purified PCR product, 10 µL of Multiplex PCR mastermix (Qiagen, Hilden, Germany) plus 5 µM
of barcoding primer in a final reaction volume of 20 µL. Cycling conditions were 98 ◦C for 5 min,
followed by 15 cycles of 95 ◦C for 30 s, 62 ◦C for 30s and 72 ◦C for 1 min, followed by 72 ◦C for
5 min. Amplicons were purified for a second time using Zymo-Spin Columns (Zymo Research, Irvine,
USA) and quantified using a Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific, Waltham, USA).
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DNA libraries were then pooled and sequenced on a MiSeq (Illumina Inc., San Diego, USA) using
2 × 80 cycles paired-end settings.
2.4. Bioinformatic Analysis
FASTQ files obtained from the MiSeq were quality-trimmed using Trimmomatic (v0.32), removing
all reads below a quality score threshold of 30. Reads were aligned to the human genome, hg19,
using Bowtie2 (v2.2.3). Alignment files were pre-processed, and duplicates were removed using a
combination of Picard tools (v1.97) and Samtools (v0.1.19). Genomic coordinates plus reference and
alternative alleles of the variant of interest were obtained using Mutalyzer API and BioPython-Entrez,
respectively. Allele counts were acquired using the Platypus (v0.8.1) variant caller.
Fetal fractions were calculated using allele ratios of 42 highly heterozygous SNPs amplified within
the maternal cfDNA. SNPs with a minor allelic ratio 0.01–0.13, indicating fetal origin, were used to
calculate the cell-free fetal fraction (cffDNA) using the formula
cffDNA% =
2×Allele B
Allele A + Allele B
× 100
To determine if the fetus had inherited the wild-type or mutant RB1 allele, mutant allele ratios
were compared between the maternal cfDNA, maternal gDNA and control cfDNA. For an affected
diagnosis to be issued, the mutant allele was required to be present within the maternal cfDNA at
levels expected given the calculated fetal fraction and above background levels seen in the control
cfDNA. Mutant allele reads below the expected level and below or equal to levels within the control
cfDNA were diagnosed as unaffected.
2.5. Capture-Based Targeted MPS
Using criteria described previously [11], we selected 4094 SNPs from dbSNP (144) with a reported
average heterozygosity of ≥40% across a 5 Mb region on chromosome 13 (Chr13: 46,500,000–51,500,000)
containing the RB1 gene (NM_000321, Chr13: 48,877,883-49,056,122, hg19). The selected SNP coordinates
were then uploaded to the NimbleDesign software (Roche Molecular Systems, Pleasanton, USA) and
capture probes were designed using the highest stringency parameters to minimise the possibility of
non-specific capture. The overall captured area was 260 Kb and SNPs were evenly distributed between
the centromeric (1533 SNPs) and telomeric (1238 SNPs) regions flanking the RB1 gene.
Capture-based MPS was performed as previously described [11]. In brief, DNA libraries were
prepared from 20 to 100 ng input DNA. Up to 12 samples, equivalent to three prenatal diagnoses
plus control samples, were multiplexed per run and sequenced on the MiSeq sequencing platform
using 2 × 80 cycles paired-end settings. Bioinformatic analysis included quality trimming of reads,
alignment to genome build hg19, removal of duplicates and variant calling to obtain SNP counts.
2.6. Relative Haplotype Dosage Analysis
Relative haplotype dosage (RHDO) measures the allelic imbalance between two haplotypes in
plasma cfDNA to determine which haplotype has been inherited by the fetus. Haplotype phasing is
conducted through genotyping of SNPs within the genomic DNA of the mother, father and a previous
child [13,14]. For NIPD testing of mothers known to carry an RB1 mutation, RHDO analysis was
performed on the maternal chromosome, as described previously [12]. In brief, RHDO was achieved
by firstly identifying the haplotype linked with the wild-type/mutant allele by DNA sequencing highly
heterozygous bi-allelic SNPs within the RB1 region in the previous child (unaffected or affected).
The genotypes of the same SNPs are then determined in maternal and paternal DNA samples to allow
haplotype phasing and to identify the maternal haplotypes linked with the mutant and wild-type alleles.
To ascertain which haplotype has been inherited by the fetus, SNPs that are heterozygous in
the mother and homozygous in the father are selected and allele counts are obtained from maternal
cfDNA sequencing. These SNPs are split into two groups (alpha and beta) depending on the genotype
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of the previous child. For alpha SNPs, the paternal allele inherited by the proband is identical to
the maternal mutant allele. In the case of beta SNPs, the proband paternal allele is the same as the
maternal wild-type allele. Alpha and beta SNPs are analysed separately and grouped into maternal
haplotype blocks of a minimum of 25 SNPs, with each block representing a statistically independent
result. Fetal fraction for each plasma sample was determined using SNPs that are homozygous in both
parents but for alternative SNP alleles, i.e., AA and BB, as described previously [11,12].
2.7. Confirmation Testing
Confirmation testing of all prenatal results was performed by Sanger sequencing of DNA extracted
from a postnatal cord blood sample at the Manchester Centre for Genomic Medicine following their
routine diagnostic protocol.
3. Results
3.1. Amplicon-Based MPS
NIPD for Rb was requested by six couples with paternal history of retinoblastoma and six couples
with a previous child identified as carrying a suspected de novo RB1 single nucleotide variant (SNV).
Following successful validation, NIPD for Rb was performed on 12 pregnancies. Maternal blood was
taken at an average of 21 weeks’ gestation (range 12–35). Cell-free DNA extracted from the maternal
plasma was amplified alongside maternal gDNA, paternal gDNA and control cfDNA. Genomic DNA
from the previous affected child was also included as a positive control where the identified germline
mutation was likely de novo.
In couples where the father was affected with Rb, the paternal mutation was detected in the
maternal cfDNA in three cases (Figure 1). In two families, the fetus was shown to be unaffected.
One additional couple underwent successful NIPD validation but gave birth prior to full testing and
newborn testing was performed in this instance.
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Figure 1. Graphical representation of the mutant allele % detected in both maternal cfDNA (green) and
maternal gDNA (blue) for each family tested by amplicon-based MPS. The maternal cfDNA mutant allele %
is an average of two duplicate samples. The maximum mutant allele % detected in the five control cfDNA
samples is also shown (black dotted line). Tests reported as predicted to be affected are indicated with a star.
All three fetuses shown to be gene carriers were delivered at term and early newborn assessment
and treatment were expedited. Three of the six eyes had grade A tumours at first assessment and
all retinoblastomas were treated solely with thermotherapy. At follow-up (2–5 years), one eye had a
logMAR score of 0.14 and the remaining eyes had logMAR scores of 0.1 or better.
For the six unaffected couples, who had a previous child with a germline RB1 mutation
(total pregnancies = seven), all fetuses were found to be unaffected (Figure 1). Full results including
read counts can be found in Table 1.
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Table 1. Non-invasive prenatal diagnosis (NIPD) results for paternal and de novo RB1 mutations by amplicon-based MPS. Read counts are given for both wild-type
(WT) and mutant (MUT) alleles in each sample tested, with the overall percentage of mutant reads (Mut %) also shown. Maternal cfDNA results are the average of two
duplicate samples. Cell-free DNA control results are the average reads from five plasma control cfDNA samples. Max mutant % refers to the highest mutant allele %
across all five control plasma samples and denotes the background threshold. TBC indicates pregnancies ongoing.
Family RB1
Mutation
Basis of
Test
Gestation
(weeks)
Fetal
Fraction
(%)
Maternal cfDNA Maternal gDNA cfDNA Control Paternal gDNA Proband gDNA
Test Result Result
ConfirmedWT MUT
Mut
% WT MUT
Mut
% WT MUT
Mut
%
Max
Mut % WT MUT
Mut
% WT MUT
Mut
%
A c.1735C>T Paternal 16 2.37 127,106 1622 1.26 155,826 241 0.15 109,510 164 0.15 0.21 80,200 81,497 50 NA Mutation Present Yes
B c.1498+1G>C Paternal 20 4.02 61,428 187 0.30 62,084 13 0.02 60,061 10 0.02 0.03 30,633 31,109 50 NA Mutation Present Yes
C c.1072C>T Paternal 12 13.5 140,559 266 0.19 162,249 264 0.16 133,482 244 0.18 0.25 71,898 68,025 49 NA No Mutation Detected Yes
D c.1238A>T Paternal 31 17.2 39,405 4888 11.03 60,681 25 0.04 57,778 50 0.09 0.17 50,872 53,671 51 NA Mutation Present Yes
E c.1075A>T Paternal 21 9.91 51,651 18 0.03 44,449 7 0.02 37,074 15 0.04 0.05 18,838 21,515 53 NA No Mutation Detected TBC
F c.1039dupT De novo 28 8.41 20,437 8 0.04 19,163 15 0.08 16,119 8 0.05 0.09 15,616 7 0.04 14,914 12,887 46 No Mutation Detected Yes
G c.1199dupT De novo 20 10.4 74,901 23 0.03 82,034 21 0.03 74,392 29 0.04 0.06 71,395 35 0.05 69,513 61,300 47 No Mutation Detected Yes
H c.1333C>T De novo 35 11.4 5713 21 0.37 6015 13 0.22 5148 18 0.35 0.55 5448 22 0.40 2668 2713 50 No Mutation Detected Yes
I_1 c.1333C>T De novo 12 7.99 25,603 43 0.17 23,721 23 0.10 22,731 40 0.18 0.23 21,609 36 0.17 18,880 19,798 51 No Mutation Detected Yes
I_2 c.1333C>T De novo 30 17.5 12,870 24 0.19 12,233 12 0.10 10,686 20 0.18 0.38 10,727 17 0.16 8519 8422 50 No Mutation Detected Yes
J c.1072C>T De novo 16 8.52 585,218 2411 0.41 743,564 2649 0.35 641,821 2148 0.33 0.46 566,685 2077 0.37 608,198 521,483 46 No Mutation Detected Yes
K c958C>T De novo 14 6.54 8925 9 0.10 8758 5 0.05 8481 11 0.13 0.16 7102 6 0.06 6487 6040 48 No Mutation Detected TBC
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Fetal fraction ranged from 2.4 to 17.5%. Due to the direct nature of the test, a mutant allele could
still be detected at fetal fraction <4%. However, it should be noted that a negative result in this instance
would have been reported as inconclusive. All NIPD results have been confirmed where postnatal
testing was available at the time of publication (n = 10). One case (Family A) who was part of the
NIPSIGEN validation period had invasive prenatal testing which was concordant with the NIPD result.
Where confirmation testing is not available, the pregnancies are ongoing.
3.2. Haplotype Analysis of Maternally Inherited Alleles
We performed NIPD by relative haplotype dosage for two pregnancies (Families L and M) at risk
of maternally inherited RB1 mutations.
The mother in Family L had a history of bilateral Rb (RB1 c.120_21 delinsC p.Glu40Aspfs*25) as
well as a previous child also affected with bilateral Rb. A maternal blood sample was taken during
her second pregnancy at 29 weeks’ gestation for NIPD analysis. We observed a fetal fraction of 15.3%.
After quality filtering, 401 (170 alpha and 231 beta) informative SNPs were identified, which formed
five and eight haplotype blocks, respectively, across the region (Figure 2a). All blocks indicated the
fetus had inherited the unaffected maternal chromosome. This was concordant with the postnatal
molecular result, performed on the follow-up infant gDNA sample by Sanger sequencing.
(a)
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Figure 2. Graphic representation of NIPD by relative haplotype dosage analysis (RHDO) result for
(a) Family L and (b) Family M at risk of maternal inheritance of retinoblastoma. Haplotype blocks
are represented by contiguous arrows spanning a 5 Mb genomic region on chromosome 13 (black
line) containing RB1 (orange bar). Red arrows indicate the fetus has inherited the mutated maternal
(M-ma) allele. Blue arrows indicate the fetus has inherited wild-type (N-ma) alleles. The position of
informative single nucleotide polymorphisms (SNPs) used to identify haplotype blocks is shown for
both alpha (green triangles) and beta (green crosses) SNPs.
The mother in Family M had a history of bilateral Rb (RB1 c.1498 + 1 G > T) and a previous child
who was also heterozygous for the mutation. A maternal blood sample was taken during her second
pregnancy at 24 weeks’ gestation for NIPD analysis. We observed a fetal fraction of 14.11%. A total of
325 (175 alpha and 150 beta) informative SNPs were identified, which formed seven alpha and six beta
haplotype blocks across the region (Figure 2b). In this analysis, all haplotype blocks indicated that
the fetus had inherited the maternal chromosome carrying the RB1 c.1498 + 1 G > T mutation and
therefore would be affected. As of September 2020, this pregnancy is still ongoing and confirmation
testing will be performed on postnatal cord blood.
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3.3. NIPD of 2 Mb RB1 De Novo Deletion
Family N had previously had a child with bilateral Rb, which was shown by microarray
analysis to have been caused by a deletion of approximately 2 Mb which incorporated the RB1 gene
(arr[hg19]13q14.2(47466483_49514186)x1). This deletion was not observed in the parents and therefore
likely de novo. Due to the possibility of germline mosaicism, the couple requested NIPD when
pregnant with their second child and a maternal blood sample was taken at 23 weeks’ gestation.
Due to the size of the mutation, amplicon-based testing was not possible. We therefore performed
capture-based MPS targeted to the 5 Mb RB1 region. As with NIPD by RHDO, informative SNPs were
genotyped within the maternal cfDNA, maternal and paternal gDNA plus genomic DNA of the child
carrying the ~2 Mb deletion. SNPs which were AA in the mother and BB in the father (known as Type 1
SNPs [13]) were then selected across the region for further analysis. In normal inheritance, a child will
be heterozygous AB for type 1 SNPs. In Figure 3, we show that the previous affected child of Family
N is heterozygous (average paternal allele frequency = 50.62%) either side of the ~2 Mb deletion but
homozygous for the maternal allele within this region (average paternal allele frequency = 0.21%),
indicating that the deletion is located on the paternal chromosome.
Figure 3
RB1
Figure 3. Graphic representation of the paternal allele frequency (PAF%) across the 5 Mb region of
chromosome 13 containing RB1 (orange bar) within the previous affected child (proband) gDNA
(blue line) and maternal cfDNA (red line) of Family N. The affected child is hemizygous for
chr13:47,515,019–49,482,240. The maternal cfDNA had a calculated fetal fraction of 6% and an
average of 2.83% paternal alleles across the region, indicating that the fetus is unaffected.
Analysis of the cfDNA derived from maternal plasma detected a fetal fraction of 6.25%. Where
the fetus is heterozygous for a type 1 SNP, we would therefore expect to detect the paternal allele at
a frequency of ~3%. Paternal alleles were detected within the maternal cfDNA across the full 5 Mb
region, including within the ~2 Mb region deleted in the previous affected child (average paternal
allele frequency = 2.83%), indicating the fetus has inherited the full 5 Mb region from the father and
was therefore predicted to be unaffected. This was confirmed through postnatal testing.
4. Discussion
Early diagnosis of retinoblastoma in individuals with a positive family history of the disease is
important not only for patient management but for family information and wellbeing. Prenatal diagnosis
of a fetus at risk offers significant benefits over newborn testing. As well as the potential for psychological
and logistical advantages, studies have shown that intra-uterine and early postnatal retinoblastoma
tumours grow rapidly and are more likely to compromise vision (reviewed in [3]). In some countries,
ultrasonography and MRI may be performed if a fetal RB1 mutation is identified prenatally. Furthermore,
a study of 20 Canadian children with familial Rb found that scheduled early-term (36–38 weeks) delivery
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following prenatal detection of an RB1 mutation led to an increase in several positive outcome measures
including reduced invasive therapy and enhanced vision [15]. However, additional validation will be
required to confirm whether improved visual outcomes are seen in a larger cohort, that treatment modality
options are not restricted by gestation and that the known negative outcomes potentially associated with
induction and early delivery do not outweigh these benefits.
Despite these possible advantages for patient management, current prenatal testing by CVS or
amniocentesis is not an attractive option to parents, and the uptake is generally low. Since October
2016, we have offered NIPD testing to couples with a paternal history of Rb and to unaffected couples
who have had a previous child affected with Rb, found to carry a likely de novo germline RB1
mutation. NIPD for couples with a maternal history of retinoblastoma is more challenging due to
excess cfDNA of maternal origin within maternal plasma. We have therefore developed NIPD for
pregnant women affected with retinoblastoma using capture-based targeted sequencing and relative
haplotype dosage. This paper describes the successful development and application of NIPD for Rb
in 14 families (15 pregnancies) with a 100% concordance rate with current postnatal testing results
(three pregnancies ongoing). Through the combination of amplicon- and capture-based targeted MPS,
we are therefore able to provide cost-effective testing for paternal and de novo mutations as well as
maternally inherited variants.
Testing is available from 8 weeks’ gestation and throughout pregnancy. For all NIPD testing,
we stipulate a minimum gestational age of 8 weeks. This is to ensure the presence of adequate
fetal-derived cfDNA within the maternal plasma. The fetal fraction is known to increase with
maternal gestation [16,17]. In our recent publication evaluating our NIPD by RHDO service on over
150 pregnancies [7], less than 6% of tests required a second sample to be taken due to a low fetal
fraction after 8 weeks’ gestation. In order to achieve a reportable result, we find that a fetal fraction
>4% is often required for both amplicon- and capture-based NIPD, although as Family A shows, it is
possible to detect the presence of a paternal or de novo mutation when the fetal load is less than this.
One limitation of NIPD for Rb testing is that, where haplotype analysis is involved, a previous
child is required in order to phase the mutant haplotype. While the previous child does not have to
be affected, this requirement still places limitations on the availability of the test. Proof-of-principle
studies have demonstrated that micro-fluidics-based linked-read sequence technology can be used
to deduce parental haplotypes directly without the need for reference samples [18,19], although the
cost analysis for this currently makes it prohibitive for routine clinical use. An alternative is the use
of grandparental samples for haplotype phasing [20,21]. While complexity and costs could prohibit
this being developed for autosomal recessive conditions, it is more suitable for dominant disorders
such as Rb, where only one set of grandparents would be required. We are therefore investigating this
alternative phasing approach.
A further limitation of haplotype analysis is the small risk (1:500–1:1000) of recombination.
Amplicon-based MPS has the advantage of directly testing the variant and so avoids this potential
issue. For this reason and the smaller technical costs involved, amplicon-based MPS is preferable to
capture-based targeted sequencing for paternal and likely de novo variants. However, the nature of
cfDNA, which is naturally fragmented to approximately 140–160 bp in length, means amplicon-based
NIPD testing is not suitable for larger paternal or de novo variants, such as indels over 10 bp. For families
where the father is known to carry an RB1 variant >10 bp, RHDO analysis is an option where the
couple has had a previous child. We have already implemented RHDO for paternal inheritance in
autosomal recessive disorders SMA and CF [7,12]. While haplotype analysis is not suitable for de
novo variants, we report a proof-of-principle case where NIPD of a variant of ~2 Mb was achieved
through capture-based targeted sequencing and direct detection. Based on the density of informative
(Type 1) SNPs observed in Families L–M, we estimate that this analysis has the potential to detect
deletions greater than 1 Mb. Although this detection would not possible where a variant resides on
the maternal chromosome, it has been found that >90% of de novo RB1 mutations are located on the
paternal chromosome [22–27], therefore increasing the likelihood of assay success. However, due to the
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cost involved in this test and the low risk to the fetus, it is unlikely this will be implemented clinically
until technology advances significantly reduce this cost.
A recent publication has confirmed that late diagnosis has a particularly detrimental impact on
patients with Rb from low to middle-income countries (LMICs) [28]. One of the co-authors of the study
previously identified a range of interventions that could impact on prognosis [29], which together with
improved treatments in those countries will significantly increase the proportion of inherited cases
in the next one to two decades. While our testing facility is based in the UK, this testing is available
for international retinoblastoma patients as only blood samples are required, which can be stable to
transport for up to five days’ post-blood draw if stored correctly. This could be of particular benefit
to retinoblastoma patients within LMICs, where access to healthcare immediately after birth can be
limited. In particular, NIPD would have significant advantages over transferring a newborn baby and
early post-partum mother over large geographical distances to achieve early intervention if required.
The feasibility of the transfer of DNA for ophthalmological genetic disorders to an international centre
from a middle-income country has been reported by Zanolli et al. [30] and would likely reduce the
need for patients with advanced Rb having to seek care on another continent [31].
In conclusion, NIPD of Rb presents a viable alternative to invasive prenatal and newborn genetic
testing, offering many advantages for both the healthcare system and the family themselves, providing
a safer and earlier diagnosis of their child.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/11/3517/s1,
Table S1: Primer sequences for amplicon-based NIPD for Rb. Table S2: Primer sequences for amplicon-based fetal
load quantification.
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